Portage Biotech (PRTG) has released an update.
Portage Biotech Inc. is reassessing its strategic options, including potential asset sales, mergers, or partnerships, following the suspension of enrollment in its ADPORT-601 clinical trial for cancer treatment due to funding challenges and market conditions. The company aims to extend its financial runway while it explores these alternatives, with no guarantee of successful transactions or terms. Portage specializes in advancing novel immuno-oncology therapies and is currently focusing on its adenosine antagonist platform.
For further insights into PRTG stock, check out TipRanks’ Stock Analysis page.
